Editor Spotlight: Dr. Maitri Kalra

Dr. Maitri Kalra

Claim this profile

Sinai Hospital of Baltimore

Studies Breast Cancer
Studies Breast cancer
8 reported clinical trials
24 drugs studied

Area of expertise

1Breast Cancer
Maitri Kalra has run 8 trials for Breast Cancer. Some of their research focus areas include:
ER positive
HER2 positive
Stage IV
2Breast Cancer
Maitri Kalra has run 6 trials for Breast cancer. Some of their research focus areas include:
HER2 positive
ER positive
Stage IV

Affiliated Hospitals

Image of trial facility.
Sinai Hospital Of Baltimore
Image of trial facility.
William E Kahlert Regional Cancer Center/Sinai Hospital

Clinical Trials Maitri Kalra is currently running

Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

More about Maitri Kalra

Clinical Trial Related2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Maitri Kalra has experience with
  • Paclitaxel
  • Usual Care Disease Monitoring
  • Serum Tumor Marker Directed Disease Monitoring
  • Trastuzumab
  • Pertuzumab
  • Radiation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Maitri Kalra specialize in?
Is Maitri Kalra currently recruiting for clinical trials?
Are there any treatments that Maitri Kalra has studied deeply?
What is the best way to schedule an appointment with Maitri Kalra?
What is the office address of Maitri Kalra?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security